1 / 8

Polycythemia Vera Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by Delve

DelveInsight's "Polycythemia Vera - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

sthakur
Download Presentation

Polycythemia Vera Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by Delve

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Polycythemia Vera Polycythemia Vera Market Analysis, Market Size, Epidemiology, Leading Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by Companies, Drugs and Competitive Analysis by DelveInsight DelveInsight DelveInsight has launched a report on “Polycythemia Vera - Market Insights, Epidemiology, and Market Forecast-2030” DelveInsight's "Polycythemia Vera - Market Insights, Epidemiology, and Market Forecast- 2030" report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the Facts: 1.According to DelveInsight, total prevalent population of Polycythemia Vera (PV) in the 7MM was found to be 301,833 in 2017. 2.Most of the diagnosed prevalence of PV was found in the United States with 107,760 cases in 2017. 3.Japan had 22,974 diagnosed prevalent cases for PV in 2017. 4.Among EU5, Germany had the highest diagnosed prevalent population of PV with 12,085 cases View Report: https://www.delveinsight.com/report-store/polycythemia-vera-market Key facts of the report: 1. Polycythemia Vera market report covers a descriptive overview and comprehensive insight of the Polycythemia Vera epidemiology and Polycythemia Vera market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 2. Polycythemia Vera market report provides insights on the current and emerging therapies. 3. Polycythemia Vera market report offers a global historical and forecasted market covering drug outreach in 7MM. 4. Polycythemia Vera market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Polycythemia Vera market. Request for Sample Pages:https://www.delveinsight.com/sample-request/polycythemia-vera- market “As per DelveInsight’s analysis, the therapeutic market of Polycythemia Vera (PV) in the seven major markets was assessed to be USD 1,099.54 million in 2017”

  2. View Report: https://www.delveinsight.com/report-store/polycythemia-vera-market Polycythemia Vera (PV) is a rare condition characterized by the progressively increased number of red blood cells in bloodstream, white blood cells (WBC) and platelets also increase in number in the affected people. This condition is known as myeloproliferative neoplasms, where the body produces too many of these cells (RBC, WBC and Platelets). These new cells cause the blood to be thicker than usual, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins, deep in the arms and the legs, it is known as deep vein thrombosis (DVT). Mutation in the JAK2 kinase is responsible for PV. Most cases of PV are associated with genetic changes that are somatic, not in the egg and sperm cells, which pass on genetic information to offspring. The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2. Bone marrow aspiration and biopsy are also done to confirm whether or not a person has PV. The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets. View Report: https://www.delveinsight.com/report-store/polycythemia-vera-market Some of the key companies working on Polycythemia Vera are:  AstraZeneca  Array Biopharma  SpringWorks Therapeutics And Many Others. The launch of the emerging therapies is expected to significantly impact the Polycythemia Vera treatment scenario in the upcoming years:- Drugs Covered:  Jakafi (Ruxolitinib): Incyte Corporation/Novartis  Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia  Idasanutlin: Hoffmann-La Roche  KRT-232: Kartos Therapeutics And Many Others002E Request for Sample Pages:https://www.delveinsight.com/sample-request/polycythemia-vera- market View Report: https://www.delveinsight.com/report-store/polycythemia-vera-market Table of Contents: 1. Key Insights 2. Executive Summary 3. Polycythemia Vera (PV) Market Overview at a Glance

  3. 3.1. Market (%) Distribution of PV in 2017 3.2. Market (%) Distribution of PV in 2030 4. Polycythemia Vera (PV): Disease Background and Overview 4.1. Introduction 4.2. Polycythemia Vera: A Type of MPN 4.3. Signs and Symptoms of Polycythemia Vera 4.4. Causes of Polycythemia Vera 4.5. Complications due to Polycythemia Vera 4.6. Clinical Aspects of Polycythemia Vera 4.7. Pathophysiology of Polycythemia Vera 4.7.1. JAK2 V617F in Polycythemia Vera 4.8. Diagnosis of Polycythemia Vera 4.9. Diagnostic Guidelines 4.9.1. British Society for Hematology Guidelines for Polycythemia Vera (PV) 4.9.2. WHO Diagnostic Guidelines 4.9.3. British Society for Hematology Guideline 5. Case Reports 6. Epidemiology and Patient Population 6.1. Methodology 6.2. Key Findings 6.3. Total Prevalent Population of Polycythemia Vera in the 7MM 6.4. Total Diagnosed Prevalent Population of Polycythemia Vera in the 7MM 6.5. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in the 7MM 6.6. Age-Specific Diagnosed Prevalence of Polycythemia Vera in the 7MM 6.7. Diagnosed Prevalence of Polycythemia Vera by Gene Mutation in the 7MM 7. United States Epidemiology 7.1. Assumptions and Rationale 7.2. KOL Insights 7.3. Total Prevalent Population of Polycythemia Vera in the United States 7.4. Total Diagnosed Prevalent Population of Polycythemia Vera in the United States 7.5. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in the United States

  4. 7.6. Age-Specific Diagnosed Prevalence of Polycythemia Vera in the United States 7.7. Diagnosed Prevalence of PV by Gene Mutation in the United States 8. EU5 Epidemiology 8.1. Germany Epidemiology 8.1.1. Assumptions and Rationale 8.1.2. Total Prevalent Population of Polycythemia Vera in Germany 8.1.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Germany 8.1.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Germany 8.1.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Germany 8.1.6. Diagnosed Prevalence of PV by Gene Mutation in Germany 8.2. France Epidemiology 8.2.1. Assumptions and rationale 8.2.2. Total Prevalent Population of Polycythemia Vera in France 8.2.3. Total Diagnosed Prevalent Population of Polycythemia Vera in France 8.2.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in France 8.2.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in France 8.2.6. Diagnosed Prevalence of PV by Gene Mutation in France 8.3. Italy Epidemiology 8.3.1. Assumptions and Rationale 8.3.2. Total Prevalent Population of Polycythemia Vera in Italy 8.3.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Italy 8.3.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Italy 8.3.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Italy 8.3.6. Diagnosed Prevalence of PV by Gene Mutation in Italy 8.4. Spain Epidemiology 8.4.1. Assumptions and Rationale 8.4.2. Total Prevalent Population of Polycythemia Vera in Spain 8.4.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Spain 8.4.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Spain 8.4.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Spain 8.4.6. Diagnosed Prevalence of PV by Gene Mutation in Spain

  5. 8.5. United Kingdom Epidemiology 8.5.1. Assumptions and Rationale 8.5.2. Total Prevalent Population of Polycythemia Vera in the United Kingdom 8.5.3. Total Diagnosed Prevalent Population of Polycythemia Vera in the United Kingdom 8.5.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in the United Kingdom 8.5.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in the United Kingdom 8.5.6. Diagnosed Prevalence of PV by Gene Mutation in the United Kingdom 8.6. KOL Insights 9. Japan Epidemiology 9.1. Assumptions and Rationale 9.2. KOL Insights 9.3. Total Prevalent Population of Polycythemia Vera in Japan 9.4. Total Diagnosed Prevalent Population of Polycythemia Vera in Japan 9.5. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Japan 9.6. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Japan 9.7. Diagnosed Prevalence of PV by Gene Mutation in Japan 10. Treatment Algorithm, Current Treatment, and Medical Practices 10.1. Treatment Algorithm 10.2. Proposed Guidelines for Polycythemia Vera 10.2.1. A British Society for Haematology Guidelines for PV 10.2.2. National Comprehensive Cancer Network (NCCN) Guidelines for Polycythemia Vera (PV) 10.2.3. European Society for Medical Oncology Guidelines for Polycythemia Vera 11. Unmet Needs 12. Marketed Products 12.1. Jakafi (Ruxolitinib): Incyte Corporation/Novartis 12.1.1. Drug Description 12.1.2. Regulatory Milestones 12.1.3. Clinical Development 12.1.4. Safety and Efficacy 12.1.5. Product Description 12.2. Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia

  6. 12.2.1. Product Description 12.2.2. Mechanism of Action 12.2.3. Regulatory Milestones 12.2.4. Advantages and Disadvantages 12.2.5. Clinical Development 12.2.6. Safety and Efficacy 12.2.7. Product Profile 13. Emerging Therapies 13.1. Key Cross Competition 13.2. Idasanutlin: Hoffmann-La Roche 13.2.1. Product Description 13.2.2. Other Developmental Activities 13.2.3. Advantages and Disadvantages 13.2.4. Clinical Development 13.2.5. Clinical Trials Information 13.2.6. Safety and Efficacy 13.2.7. Product Profile 13.3. KRT-232: Kartos Therapeutics 13.3.1. Product Description 13.3.2. Clinical Development 13.3.3. Clinical Trials Information 13.3.4. Product Profile 13.4. Givinostat: Italfarmaco 13.4.1. Product Description 13.4.2. Other Developmental Activities 13.4.3. Advantages and Disadvantages 13.4.4. Clinical Development 13.4.5. Clinical Trials Information 13.4.6. Safety and Efficacy 13.4.7. Product Profile List to be continued in the report………

  7. 14. Polycythemia Vera (PV): 7MM Market Analysis 14.1. Key Findings 14.2. Market Size of Polycythemia Vera in 7MM 14.3. Market Size of Polycythemia Vera by Therapies in the 7MM 15. United States: Market Outlook 15.1. United States Market Size 15.1.1. Total Market size of Polycythemia Vera in the United States 15.1.2. Market Size of Polycythemia Vera by Therapies in the US 16. EU-5 countries: Market Outlook 16.1. Germany Market Size 16.1.1. Total Market size of Polycythemia Vera in Germany 16.1.2. Market Size of Polycythemia Vera by therapies in Germany 16.2. France Market Size 16.2.1. Total Market size of Polycythemia Vera in France 16.2.2. Market Size of Polycythemia Vera by therapies in France 16.3. Italy Market Size 16.3.1. Total Market size of Polycythemia Vera in Italy 16.3.2. Market Size of Polycythemia Vera by therapies in Italy 16.4. Spain Market Size 16.4.1. Total Market size of Polycythemia Vera in Spain 16.4.2. Market Size of Polycythemia Vera by therapies in Spain 16.5. United Kingdom Market Size 16.5.1. Total Market size of Polycythemia Vera in the United Kingdom 16.5.2. Market Size of Polycythemia Vera by therapies in the UK 17. Japan Market Outlook 17.1. Japan Market Size 17.1.1. Total Market size of Polycythemia Vera in Japan 17.1.2. Market Size of Polycythemia Vera by therapies in Japan 18. Market Drivers 19. Appendix 19.1. Report Methodology

  8. 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight View Report: https://www.delveinsight.com/report-store/polycythemia-vera-market

More Related